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Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder involving both upper motor neurons
(UMN) and lower motor neurons (LMN). Enormous research has been done in the past few decades in unveiling
the genetics of ALS, successfully identifying at least fifteen candidate genes associated with familial and sporadic
ALS. Numerous studies attempting to define the pathogenesis of ALS have identified several plausible determinants
and molecular pathways leading to motor neuron degeneration, which include oxidative stress, glutamate
excitotoxicity, apoptosis, abnormal neurofilament function, protein misfolding and subsequent aggregation,
impairment of RNA processing, defects in axonal transport, changes in endosomal trafficking, increased
inflammation, and mitochondrial dysfunction. This review is to update the recent discoveries in genetics of ALS,
which may provide insight information to help us better understanding of the disease neuropathogenesis.
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Amyotrophic lateral sclerosis (ALS) is a heterogeneous
group of neurodegenerative disorders characterized by
progressive loss of motor neurons of the primary motor
cortex, brainstem and spinal cord, consequently resul-
ting in muscle weakness, paralysis and ultimately the
death [1]. Patients present with either limb onset (80%
cases) or bulbar onset (20% cases). In limb onset cases,
symptoms appear either distally or proximally in either
the upper or lower limb. Bulbar onset cases usually
manifest with dysarthria and dysphagia, and limb symp-
toms can develop along with bulbar symptoms or may
occur in the due course of the disease within a year [1].
Most ALS patients come across both upper motor
neuron (UMN) and low motor neuron (LMN) signs.
The typical age onset is about 55 years [2]. It progresses
at a fast pace with most of the patients dying within
3–5 years of the onset [2]. However there is also a small
subset of ALS cases that present with a relatively slower
disease course. The incidence of the disease is approxi-
mately similar worldwide ranging from 1 to 2 new cases* Correspondence: wdle@sibs.ac.cn
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reproduction in any medium, provided the orper 100,000 individuals every year and the prevalence is
around 4–6 cases per 100,000 individuals [2].
ALS has no definitive diagnostic test and it is diagnosed
clinically in most cases. There is no cure for ALS, although
the only FDA approved drug Riluzole may increase certain
ALS patient survival by 3 months [3]. Considerable pro-
gress has been made in comprehending the genetics of
ALS in the past decade. Interestingly, recent studies have
demonstrated that ALS may be a multisystem neurode-
generative disease in which brain and brain stem are also
affected [1-3]. For example, several cases suffered from
ALS exhibit symptoms of cognitive impairment, which is
pathologically characterized by cytoplasmic ubiquitin-
positive inclusions in hippocampus and neocortical neu-
rons in addition to anterior horn neurons [1-3]. In this
review, we summarize the genetic breakthroughs in famil-
ial ALS (fALS) and sporadic ALS (sALS) and depict how it
shapes our understanding of disease pathogenesis and our
quest for rational therapies.Genetics of ALS
ALS can be inherited in an autosomal dominant, auto-
somal recessive, or X-linked manner. 90% ALS are spor-
adic cases with no clear genetic linkage. However, the
remaining 10% of cases show familial inheritance [4,5].td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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http://www.molecularneurodegeneration.com/content/8/1/28In the last few years, there has been a rapid advance in
our knowledge of genetic causes for ALS. Furthermore,
the relationship between the genetic subtypes and the
pathological subtypes as well as clinical phenotype has
become more and more clear. In addition to superoxide
dismutase 1 (SOD1), mutations in the genes coding for
TAR DNA-Binding Protein (TARDBP), fused in sarcoma
(FUS), Ubiquilin2 (UBQLN2), C9ORF72 and several
others are closely associated with typical clinical pheno-

































Figure 1 ALS is caused by interplay of various molecular pathways in
neuronal cells like microglia and astrocytes. Microglial cells activate an
motor neuron injury through release of inflammatory mediators such as ni
and oxidative stress, aberrant RNA processing, protein misfolding and insol
aggregation may lead to endoplasmic reticulum stress along with defectiv
organelle disruption and activates autophagy and apoptotic pathways. Axo
along with the defective axonal growth and axonal dysfunction. Axonal dy
contribute to motor neuron degeneration in ALS.defects in ALS and the underlying mechanisms for the
cause and pathogenesis of the disease.
Genetics of fALS
The causative genes have been identified in almost
5-10% of all fALS cases to date [4,5]. Among those 20%
of fALS cases are caused by the mutation in SOD1 gene,
4-5% of fALS cases are the results of mutations in
TARDBP and FUS genes, more than 30% of fALS cases

























motor neurons and an interaction with neighbouring non-
inflammatory cascade via secretion of cytokines. Astrocytes lead to
tric oxide and prostaglandin E2. Accumulation of superoxide radicals
uble proteins may cause motor neuron degeneration in ALS. Protein
e endosomal trafficking and mitochondrial damage, which may cause
nal transport abnormalities lead to energy deficiency in the axon
sfunction, defective angiogenesis and metabolic disturbance may




locus Gene Protein Onset Inheritance Clinical feature
Other diseases
caused by the gene
ALS1 21q22.1 SOD1 Cu/Zn SOD-1 Adult AD/AR Typical ALS NA
ALS2 2q33-2q35 Alsin Alsin Juv AR
Slowly progressive, predominantly UMN
signs like limb, & facial spasticity
PLS IAHSP
ALS3 18q21 Unknown Unknown Adu AD
Typical ALS with limb onset
especially lower limb
NA
ALS4 9q34 SETX Senataxin Juv AD
Slowly progressive, distal hereditary
motor neuropathy with pyramidal signs
SCAR 1 and AOA2
ALS5 15q15-21 SPG 11 Spatacsin Juv AR Slowly progressive HSP
ALS6 16p11.2 FUS Fused in Sarcoma Juv/Adu AD/AR Typical ALS NA
ALS8 20q13.3 VAPB VAPB Adu AD Typical and atypical ALS SMA




Adu AD Typical ALS NA




Rapid progressive with prominent
corticospinal tract signs
CMT 4 J
ALS12 10p13 OPTN Optineurin Adu AD/AR
Slowly progressive with limb onset
and predominant UMN signs
Primary Open Angle
Glaucoma
ALS14 9p13.3 VCP VCP Adu AD Adult onset, with or without FTD IBMPFD
ALS15/
ALSX
Xp11 UBQLN2 Ubiquilin 2
Adu/Juv
XD UMN signs proceeding LMN signs NA
ALS16 9p13.2-21.3 SIGMAR1 SIGMAR1 Juv AR Juvenile onset typical ALS FTD
ALS-FTD1 9q21-22 unknown unknown Adu AD ALS with FTD FTD
ALS-FTD2 9p21 C9ORF72 C9ORF72 Adu AD ALS with FTD FTD
NA 2p13 DCTN1 Dynactin Adu AD
Distal hereditary motor
neuropathy with vocal paresis
NA
Other rare-occurring ALS genes
ALS3 18q21 Unknown Unknown Adu AD
Typical ALS with limb onset especially
lower limb
NA
ALS7 20ptel-p13 Unknown Unknown Adu AD/AR Typical ALS NA
NA 12q22-23 DAO DAO Adu AD Typical ALS NA
Up to date, more than 20-ALS genes have been identified in fALS. These genetic mutations represent different molecular pathways of motor neuron degeneration.
Abbreviations for Table 1: PLS Primary Lateral Sclerosis, IAHSP Infantile onset ascending hereditary spastic paralysis, SCAR 1 Autosomal Recessive Spino-cerebellar
ataxia, AOA2 Ataxia Ocular Apraxia 2, HSP Hereditary spastic paraplegia, VAPB Vesicle associated membrane protein associated protein B, SMA Spinal Muscular
Atrophy, CMT 4 J Charcot-Marie Tooth disease type 4 J, VCP Valosin Containing Protein, IBMPFD Inclusion body myopathy with Pagets disease and fronto temporal
dementia, SIGMAR1 Sigma Non Opiod Intracellular Receptor, C9ORF72 Chromosome 9 open reading frame 72, PD Parkinson disease, DAO D-Amino Acid Oxidase,
FTD Frontal-temporal dementia, AD Autosomal dominant, AR Autosomal recessive.
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csin, vesicle associated membrane protein associated
protein B (VAPB). angiogenin (ANG), factor induced
gene 4 (FIG 4), optineurin (OPTN) and perhaps other
unknown genes [see Table 1].
ALS1/ superoxide dismutase 1(SOD1)
SOD1 is the first gene to be identified in fALS based on
linkage analysis in autosomal dominant fALS pedigrees,
which maps to chromosome 21q22.1 [5]. Individuals
with mutant SOD1 present mostly with limb onset,
starting predominantly in lower limb rather than upper
limb. A few cases also present with bulbar onset. To date
more than 150 mutations have been found in all 5 exonsaffecting the functional domains of SOD1 predominantly
in missense mutations, although a small percentage of
nonsense mutations, insertions and deletions have also
been reported. Mutations in SOD1 have been reported
in ~20% of fALS and in ~1-4% of sALS [2]. SOD1 mu-
tant ALS cases show ample variation in the phenotype
in the age of onset, severity, rate of disease progression
and duration. SOD1 genotype analysis illustrates variable
clinical phenotypes, indicating that the phenotype is
modified by genetic as well as environmental factors [4].
The SOD1D90A mutation which is recessive in a Scandi-
navian population is shown to be related with autosomal
dominant ALS in other genetic groups [2]. Patients car-
rying the SOD1A4V mutations have shorter survival with
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diagnosis, and the penetrance of the gene mutation is
91% [2]. The SOD1A89V mutation has incomplete pene-
trance, variable age at onset and sensory neuropathy [6].
The SOD1I113T mutation is highly diverse in the age of
onset, clinical manifestations, disease progression and
penetrance [7,8].
SOD1 is a cytoplasmic protein, which is a homodimer
of 153 amino acids, containing one copper and one zinc
atom [2,5]. Copper plays a role in SOD1 activity,
whereas zinc is contributed to structural stability. SOD1
detoxifies superoxide radicals, a by-product of oxidative
phosphorylation, to hydrogen peroxide and oxygen,
which are converted to water and oxygen by catalase
and glutathione peroxidase enzymes [2,5]. The exact
mechanism by which SOD1 mutations lead to ALS path-
ology is unknown although numerous hypotheses have
been proposed to explain SOD1-mediated toxicity such
as misfolding proteins-associated aggregation, oxidative
stress, mitochondrial dysfunction, endoplasmic reticu-
lum stress, glutamate excitotoxicity, inflammation and
microglial activation and axonal transport abnormalities
[2,5]. Several mutant SOD1 transgenic mice have been
generated and SOD1G93A mice are the mostly used
model for ALS studies [9]. This mouse model has been
successfully used in variety of studies to define the mo-
lecular mechanism of the disease and evaluate new drug
responses [9]. Interestingly, SOD1 knockout mice do not
develop ALS, although they do exhibit some age-
dependent distal motor neuropathy compared with
SOD1G93A mice, which supports the notion that toxic
gain of function may be responsible for the motor
neuron degeneration in SOD1G93A mice since enzymatic
activity is retained in SOD1G93A mutation [10].
ALS2/ALSIN
ALS2 is a rare, autosomal recessive, juvenile onset (mean
age at onset is 6.5 years) disease characterized by limb
and facial spasticity, spastic dysarthria, uncontrolled
laughter, subsequent lower motor neuron signs and
bladder dysfunction [2,11]. The locus of ALS2 is mapped
to chromosome 2q33-2q35 via linkage analysis in a large
Tunisian kindred [2,11]. The deletion mutations result
in frame shifts that result in a premature stop codon.
Alsin is alternatively spliced to produce a long and a
short transcript. Deletion mutations in the short tran-
script cause ALS2 and those in the long transcript lead
to juvenile primary lateral sclerosis (PLS) [11]. Alsin is a
Rab5 and Rac1 guanine nucleotide exchange factor
(GEF) domains. It promotes neurite outgrowth in cell
cultures through activation of the small GTPase Rac1
macropinocytosis-associated endolysosomal trafficking
via the fusion between endosomes and autophagosomes
[11]. Alsin protects cultured motor neurons frommutant SOD1 toxicity suggesting its neuroprotective
role [12]. Overexpression of alsin inhibits mutant
SOD1G93A-induced endosomal Rac1 activation and re-
active oxygen species production [13,14]. The mutations
in alsin may induce a loss of this neuroprotective func-
tion by disrupting the endolysomal system and causing
an aggregation of immature vesicles and misfolded pro-
teins in neurons [13,14]. Alsin knock-out mice models
demonstrate that the loss of alsin can result in motor
neuron damage, but no definitive features consistent
with ALS or other motor neuron disease. However, not
all the studies support that alsin knock-out mice might
develop motor neuron degeneration. Cai et al. and Gros-
Louis et al. reported that alsin knock-out mice displayed
signs of corticospinal track degeneration but did not de-
velop obvious progressive motor neuron degeneration
[15,16]. These mice have increased vulnerability to oxi-
dative stress, indicating that alsin variants might be a
risk factor rather than directly cause of motor neuron
degeneration [15,16].
ALS4/senataxin (SETX)
ALS4 is a rare, juvenile onset, autosomal dominant ALS,
characterized by distal limb weakness, muscle atrophy,
and pyramidal signs [1,2,17]. Bulbar and respiratory
muscles are spared. Disease progression is slow and the
patients usually have a normal life span [1,2,17]. ALS4 is
linked to chromosome 9q34 [17] and sequencing 19
genes in this locus reveals 3 distinct missense mutations
in the SETX gene in 3 families with ALS [18]. In
addition, positional cloning technique reveals that
the mutations in SETX gene in the locus also asso-
ciated with autosomal recessive spinocerebellar ataxia-1
(SCAR1), which is also referred to ataxia-ocular apraxia-
2 (AOA2) [19]. SETX gene encodes a ubiquitously
expressed DNA/RNA helicase protein [19,20]. SETX and
DNA/RNA helicases are involved in DNA repair, replica-
tion, recombination, transcription, RNA processing,
transcript stability, and the initiation of translation
[19,20]. SETX is similar to several genes involved in
RNA processing such as the immunoglobulin mu bind-
ing protein 2 gene (IGHMBP2), mutations in which are
known to cause spinal muscular atrophy with respiratory
distress type 1 [20], implying that SETX mutations-
caused motor neuron degeneration may result from the
aberrant RNA processing [21].
ALS5/spatacsin (SPG)
ALS5 also known as juvenile ALS type 1 is the most
common form of recessive fALS with juvenile onset.
Most of the cases present before the age of 25 yrs
[22,23]. It follows a slow progressive course that can sur-
vive more than 3 decades. A study in 22 patients with
ALS from 7 families links ALS5 to chromosome 15q15-
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mutations cause autosomal recessive hereditary spastic
paraplegia (HSP) with atrophied corpus callosum
[22,23], and share certain clinical, pathological and gen-
etic features of ALS according to a study in 25 families
from Italy, Brazil, Canada, Turkey, and Japan [24]. A
total of 12 mutations in SPG11 gene have been identi-
fied, out of which 10 are either nonsense mutations or
insertions or deletions leading to a frame shift, indicating
a loss of function [24]. SPG11 is a protein with four
transmembrane domains, a leucine zipper and a coil
domain. This protein is identified in central nervous
system, especially in the cortical and spinal motor neu-
rons as well as in the retina, showing multiple organelles
like protein-trafficking vesicles, endoplasmic reticulum
and microtubules, and the accumulation of spatacsin
in non-myelinated axons suggesting axonal transport
disturbance [25].
ALS6/fused in sarcoma (FUS)
ALS patients with ALS6 mutations are characterized by
a wide range of disease onset from 26–80 years with the
mean duration around 33 months [2]. Most cases show
LMN predominance, without bulbar region involvement
and no cognitive impairment. The locus for ALS6 has
been mapped to chromosome 16p11.2 encoding FUS
gene [26]. Mutations in FUS gene are identified based
on a linkage analysis in a large Cape Verde family with
autosomal recessive ALS and in numerous British kin-
dred with autosomal dominant ALS [27]. Up to now,
more than 50 FUS mutations have been identified
in ~4% cases of fALS and ~1% of sALS cases [27]. FUS
mutations are also found in fALS patients with frontal-
temporal dementia (FTD) and in juvenile ALS patients
with basophilic inclusions [28]. In addition, FUS is the
major component of nuclear polyQ aggregates of
Huntington disease (HD) as well as spinocerebellar
ataxia type 1, 2, 3, and dentatorubral-pallidoluysian atro-
phy [29]. Histopathological analysis of FUS mutant cases
illustrates distinctive FUS positive and TDP-43 negative
inclusions and an earlier age of onset is noted in cases
with basophilic and compact neuronal cytoplasmic [28].
FUS gene encodes for a DNA/RNA binding protein that
has multiple domains and the domain at N-terminus
plays a role in transcriptional activation of the gene
[30,31]. As a nuclear protein and mutations at the
C-terminus disrupt the transport of FUS into the nu-
cleus, which lead to cytoplasmic localization of FUS and
formation of stress granules [30,31]. Overexpression of
mutant FUS in a transgenic mouse model develops pro-
gressive paralysis due to motor axonal degeneration and
neuronal loss in the cortex and hippocampus [32]. In
transgenic Drosophila model, it has been observed age-
dependent progressive motor neuron damage when Wt,R524S or P525L mutant FUS are over-expressed in photo-
receptors [33]. In addition, over-expressing WT or mutant
FUS C. elegant models and knocking down endogenous
FUS Zebrafish models are both used to study the mechan-
ism of FUS mediated motor neurodegeneration [27].
ALS8/ vesicle associated membrane protein associated
protein B (VAPB)
ALS8 is first described in a large Brazilian kindred with
28 affected male and female family members from across
4 generations [34]. Clinical onset occurs between ages
31 and 45 years, and the patients present with postural
tremor, fasciculations, slow progressive upper and lower
limb weakness [34]. The disease has an unusually long
course compared to typical ALS. Linkage analysis reveals
a novel locus at chromosome 20q13.3 and the mutation
analysis depicts a mutation in the VAPB protein, which
replaces the amino acid proline with the amino acid
serine at position 56 [34]. A different mutation (T46I) is
detected within the same domain of VAPB protein in a
UK patient [35]. VAPB is an integral endoplasmic
reticulum membrane protein, which has various func-
tions such as the intracellular vesicle trafficking, lipid
transport and the unfolded protein response [34,35].
Both the mutations in the VAPB domain lead to VAPB
aggregation into immobile ER clusters which causes
lower level of VAPB, resulting in a decreased ER anchor-
ing of lipid-binding proteins and motor neuron degener-
ation [34,35]. The expression of VAPB is significantly
decreased in human ALS patients and SOD1-ALS-
transgenic mice, suggesting that VAPB may be involved
in the pathogenesis of sALS and SOD1-linked ALS [36].
A study on mutant VAPB transgenic mice shows TDP-
43 cytoplasmic inclusions, implying a link between
VAPBP56S mutation and TDP-43 mislocalization [37].
The VAPBP56S mutation alters the binding of VAPB to
tyrosine phosphatase-interacting protein 51 (PTPIP51)
and increases Ca2+ uptake by mitochondria following
the release from ER stores [38]. However, a study from
Qiu et al. shows that overexpression of VAPBP56S mu-
tant in mouse spinal cord can produce abundant VAPB
aggregates, but it is not associated with motor neuron
degeneration, indicating that the mutant VAPB aggre-
gates may cause motor neuron degeneration by loss of
function rather than gain-of-toxicity [39].
ALS9/angiogenin (ANG)
ALS caused by ANG gene mutation is named as ALS9,
an autosomal dominant adult onset disease presenting
with the classic signs of ALS. A few patients also
presented with parkinsonism and signs of FTD [40].
ANG is located at chromosome 14q11.2 and is first
identified in ALS patients from Ireland and Scotland
[40]. Seven missense mutations in ANG have been
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cohort of Irish, Scotish, English, Swedish and North
American ALS cases, out of which 4 are fALS and the
rest sALS [40]. ANG mutations are not associated with
fALS in Italian population [41]. Few fALS cases are iden-
tified to have concomitant ANG mutations with FUS
mutations [42] or with SOD1 mutations [43].
The ANG protein belongs to pancreatic ribonuclease
superfamily, and it plays a role in inhibiting of protein
translation by cleaving tRNA and helps in rRNA biogen-
esis and cellular proliferation [40,42,43]. ANG mediates
neovascularization and promotes neurite outgrowth dur-
ing early embryonic development [44]. Mutations in
ANG gene cause loss of ribonucleolytic activity and nu-
clear translocation activity [44].
ALS10/ TAR DNA binding protein (TARDBP)
Mutations of gene TARDBP was first reported in fALS
cases in 2008 [45]. Since then, over 40 mutations have
been identified in various ethnic groups with an inci-
dence of ~4-5% in fALS and up to 2% in sALS.
TARDBP-related ALS patients present as adult-onset,
autosomal dominant form of ALS with predominant
limb onset and a wide variation in the age of onset
(30–77 yrs) and disease duration. TARDBP mutations
are observed in both ALS-FTD and FTD cases.
Ubiquitinated TARDBP (TDP-43) is one of the major
components of cytoplasmic inclusions in ALS and FTD
[45]. TDP-43 positive cytoplasmic inclusions are found
in many neurodegenerative disorders such as sALS,
FTD, HD, Alzheimer’s disease (AD) and PD [46]. TDP-
43 is a DNA/RNA binding protein, belonging to ribonu-
cleoprotein family. TDP-43 is involved in a variety of
functions in nucleus process, including gene transcrip-
tion, RNA splicing, microRNA processing and stabiliza-
tion as well as transport of mRNA [47]. Almost all the
TARDBP mutations identified in ALS patients are mis-
sense mutations within the glycine-rich C-terminal
region, involved in protein-protein interactions. TDP-43
has many binding targets, including FUS, vasolin
containing protein (VCP), progranulin, and other tran-
scripts encoding neurodegenerative disease-associated
proteins as well as many other RNA processing genes
[47]. Furthermore, by using individual-nucleotide reso-
lution UV-cross linking and immunoprecipitation,
Tollervey et al. found that TDP-43 can bind to nuclear
paraspeckle assembly transcript 1 (NEAT1) and metasta-
sis associated lung adenocarcinoma transcript 1
(MALAT1) non-coding RNAs [48,49]. It can also influ-
ence alternative splicing in position-dependent manner
to Nova proteins, indicating that TDP-43 may play an
essential role in splicing regulation in central nerve sys-
tem [48,49]. TDP-43 interacts with mutant, but not
wild-type SOD1 mRNA, thereby linking the two distinctgenetic pathogenic mechanisms [50]. It is not clear how
TARDBP mutations cause motor neuron degeneration,
due to a loss of nuclear function or a gain of toxic func-
tion. Up to date, there are numerous animal models of
TDP-43. These models expressing human wild-type or
the ALS-linked mutants A315T or M337V TDP-43
(hTDP-43) under the control of the murine prion pro-
tein promoter (moPrP) display motor neuron degener-
ation, indicating gain-of-function mechanism [51,52].
Furthermore, the mice with high-expressing homozy-
gous TAR4/4 display a spastic paralysis of UMN degen-
eration [51,52]. Up-regulation of TDP-43 in motor
neurons may alter RNA metabolism via alternative spli-
cing and RNA stability, which may increase ALS risk
[51-54]. Increase of the TDP-43 level is associated with
formation of TDP-43 inclusions in the nucleus and
mislocalization of SMN–GEMs (Survival Motor Neuron
containing Gemini of coiled bodies) and alter RNA
metabolism [51,53]. On the other hand, loss of function
may also play a role. For example, the lack of TDP-43 in
forebrains of mice may lead to age-dependent brain
atrophy. It is known that loss of TDP-43 may down-
regulate Tbc1d1 protein in skeletal muscle and then
induce hypermetabolism which can compromise neur-
onal function [51,53]. Interestingly, TARDBP knockout
mice model shows decreased level of TDP-43 and body
weight reduction which may result from increasing fat
oxidation and accelerating fat loss in adipocytes [51].
ALS11/FIG 4
It is an autosomal dominant adult onset ALS with a
rapid progressive course, early bulbar involvement and
slight cognitive impairment [2]. Mutations in FIG 4 also
known as Sac1 domain containing protein 3 (SAC3)
gene located on chromosome 6q21 has been found as a
causative gene for ALS11 [2]. In a screening test
conducted for FIG 4 mutations in a large North
European cohort of fALS and sALS patients, 5 heterozy-
gous mutations, 1 missense, 2 splicing, and 2 truncating
mutations have been identified [55].
FIG 4 is a phosphoinositide 5-phosphatase that
regulates PI(3,5)P2, a signaling lipid that helps in
retrograde trafficking of endosomal vesicles to the
trans-Golgi network [56]. Mutations in FIG 4 result in
neurodegeneration in sensory and autonomic ganglia,
motor cortex, and striatum [55-57]. It is still not certain
yet whether mutations of FIG 4 cause neurodegeneration
through a dominant negative mechanism or a partial
loss of function as in Charcot-Marie Tooth disease type
4 J (CMT4J) [55]. Furthermore, mutant mice with absent
Vac14, a gene coding for an FIG 4 interactor, also shows
neurodegeneration. Mutations in the two components of
the PI(3,5)P2 regulatory complex, FIG 4 and Vac14, lead
to cytoplasmic inclusion body formation containing p62,
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tophagy may play a role in the gene mutations induced
neurodegeneration [57].
ALS12/optineurin (OPTN)
ALS12 is an adult onset autosomal recessive or auto-
somal dominant ALS characterized by lower limb onset
with UMN involvement and a slow disease progression
[2]. It maps to chromosome 10p13, a genetic analysis of
this gene reveals a homozygous deletion of exon 5 and
another homozygous nonsense (Q398X) mutation [2].
Two homozygous mutations and a heterozygous mis-
sense mutation (E478G) are identified in a large cohort
of fALS and sALS [4]. OPTN is co-localized with FUS,
TDP43 and SOD1 in inclusion bodies of sALS and fALS
[4]. In HD cortex, OPTN is seen in neuronal intranuc-
lear inclusions co-labeled with ubiquitin [4]. This protein
participates in multitasking cytosolic protein process
involved in protein trafficking, maintenance of the Golgi
complex, and exocytosis [4]. ALS12 is inherited in an
autosomal recessive manner, and the OPTN protein
causes neurotoxicity through the loss of function mech-
anism [4,5,58,59]. However, in heterozygous mutations
with autosomal dominant inheritance, dominant nega-
tive effect may play a role [4,5,58,59]. Nuclear factor-κB
(NF-κB), which is activated by tumor necrosis factor-
alpha can be regulated by OPTN and mutations in the
gene can lead to uninterrupted NF-κB neurotoxicity [4].
OPTN can be phosphorylated by protein kinase TANK
binding kinase 1 (TBK1) and then promote selective
autophagy function of ubiquitin-coated substance [59].
Furthermore, Koraj et al. found that OPTN can activate
autophagy-lysosome pathway and clearance of protein
aggregation via ubiquitin-independent manner [60].
These two studies highlight that OPTN is an important
factor in autophagy process.
ALS14/ valosin containing protein (VCP)
ALS 14 is an adult onset autosomal dominant inherited
motor neuropathy with an average disease onset of 49 yrs
[2]. The clinical character includes limb-onset motor
neuron symptoms with rapidly progress [2]. In an Italian
family with autosomal dominant ALS patients, using
exome sequencing technique, a single heterozygous mis-
sense mutation in the gene coding for VCP is located on
chromosome 9p13.3 [61]. Additional screening conducted
on the VCP gene in 210 fALS cases and 78 autopsy-
proven ALS cases has identified 3 more VCP mutations in
4 patients [61]. VCP mutations are a rare cause of fALS
and clinical features could include FTD, Paget’s disease,
inclusion body myopathy, and parkinsonism.
VCP is a hexameric type II ATPase of the AAA family
involved in multiple cellular functions, including protein
homeostasis through endoplasmic reticulum-associateddegradation (ERAD), Golgi biogenesis, assembly of per-
oxisomes, vesicle transport and fusion and autophagy
[2,61]. VCP plays a role in ER stress by activating the
unfolded protein response (UPR) that leads to aggrega-
tion of misfolded proteins and causes apoptotic cell
death [2,61]. VCP also plays a major role in ubiquitin-
dependent protein degradation [62]. Quantitative immu-
nohistochemical study of VCP in the skin from patients
with ALS and controls reveals that the proportion of
VCP-positive cells in the epidermis in ALS is higher
than that in controls and this proportion is higher in
ALS patients with longer duration of illness [63].
ALS15/ALSX/ubiquilin 2 (UBQLN2)
ALSX is an adult or juvenile onset, X-linked dominantly
inherited disease [2]. Patients present with UMN and
LMN involvement, and UMN signs typically precede
LMN signs [2]. A few of them even have dementia.
UBQLN2 gene maps to chromosome Xp11. Linkage
analysis in a 5 generation kindred with 19 affected can-
didates reveals a distinct point mutation in the coding
region of UBQLN2 gene which substituted proline with
histidine [64]. Later on 4 more missense mutations are
identified in 4 unrelated families, all substituting proline
with some other amino acid [65]. UBQLN2 is a member
of the ubiquitin like protein family, which regulates the
ubiquitin proteasome system (UPS) of protein degrad-
ation by delivering ubiquitinated proteins to proteasome
[64-66]. Mutations in UBQLN2 impairs protein degrad-
ation pathway which can lead to an abnormal protein
aggregation and neurodegeneration. UBQLN2 inclusions
can be seen in the spinal cord in patients with UBQLN2
mutations [64-66]. These inclusions are also positive for
other ALS proteins such as Ubiquitin, p62, TDP-43, FUS
and OPTN, but negative for SOD1 [64-66]. UBQLN2
inclusions are also found in fALS, sALS and ALS-
dementia cases without UBQLN2 mutations [66].
ALS16/SIGMAR1
ALS 16 is reported in a Saudi Arabian family [67].
Patients show UMN signs of spasticity and hyperreflexia
in the initial years of life, develop LMN signs later, and
progress to paralysis [67]. By homozygosity mapping, a
linkage is found on chromosome 9p13.2-21.3, and using
candidate gene sequencing, a mutation is identified in
SIGMAR1 (SIGMA Non Opiod Intracellular Receptor1)
gene [67]. Linkage studies done in 2 pedigrees, a Dutch
and a Scandinavian family established a connection
between familial ALS with FTD to chromosome 9p13.2-
21.3 [68]. In the Scandinavian family, ALS and FTD
occur separately; however, in Dutch family all the
members show both ALS and FTD symptoms [67-69].
Mutation screening in 34 genes on chromosome 9p
using linkage analysis in a multi-generation kindred with
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the 3’UTR of the SIGMAR1 gene [69]. The SIGMAR1
protein functions as a subunit of the ligand regulated
potassium channel, which can bind to neurosteroids,
psychostimulants, and dextrobenzomorphans [69]. The
3’UTR alterations of the SIGMAR1 are hypothesized to
alter the stability of the transcript and dysregulate the
channel activity [69].
ALS-FTD1 and ALS-FTD2
ALS-FTD1 is an adult onset, autosomal dominant dis-
order which presents with the symptoms of both fALS
and FTD [2,58]. ALS-FTD1 is linked to chromosome
9q21-q22 in a linkage analysis conducted on 16 ALS-
FTD pedigrees [70].
Patients with ALS-FTD2 present with an adult onset,
autosomal dominant fALS and FTD [2,71]. Linkage of
ALS-FTD2 to chromosome 9p21 has been reported and
a hexanucleotide GGGGCC repeat expansions in the
chromosome 9 open reading frame 72 (C9ORF72) gene
has recently been identified as the causal genetic defect
of ALS-FTD2 [71]. C9ORF72 repeat expansions are cur-
rently the most frequently genetic cause of fALS and
FTD, accounting for approximately 34.2 and 25.9% of
the cases, respectively [72]. C9ORF72 ALS has both
p62/ubiquitin- and TDP-43 positive inclusions. The
loss-of function and gain-of function have been pro-
posed. For clinical phenotype, C9ORF72 mutation mani-
fests FTD and ALS as well as other features including
memory loss, psychosis, akinetic-rigid and cerebellar
signs [73]. Recent studies indicate that C9ORF72 hexa-
nucleotide repeat could generate insoluble polypeptides
specific to C9RANT immunoreactivity by non-ATG
(RAN)–initiated translation, which cannot be found in
other neurodegenerative diseases such as CAG repeat
disorders [74,75]. These findings may provide evidence
for better understanding of ALS mechanisms and treat-
ment strategies targeting to non-ATG (RAN)-translated
peptides [74-76].
Dynactin (DCTN1)
In a study made on large kindred with a slow progres-
sive autosomal dominant distal hereditary motor neuro-
nopathy, a mutation has been identified in the p150
subunit of DCTN1 gene mapped on chromosome 2p13.
Later on 3 more mutations have been identified in
DCTN1 gene in sALS, fALS and ALS-FTD families [77].
Dynein is a microtubule motor protein that couples ATP
hydrolysis for cellular motility in cilia and flagella [78].
The binding of dynactin to dynein is critical in the
axonal transport of vesicles and organelles [78]. Thus
DCTN1 mutations are thought to cause neurodegene-
ration by impairing axonal transport in motor neurons.
Additionally, G59S missense mutation in microtubule-binding domain of p150glued, a major component of
dynein/dynactin complex can cause motor neuron
degeneration [79]. In G59S p150glued knock-in mice,
MND-like phenotypes appear after 10 months old. Loss
of spinal motor neurons, increase of reactive astrogliosis
and excessive accumulation of cytoskeleton and synaptic
vesicle proteins at the neuromuscular junctions are
observed [79]. The motor neuron degeneration is also
observed in mutant human dynactin p150Glued overex-
pression mice model [80]. These results indicated the
role of dynactin in ALS pathogenesis [80,81].
Other rare occurring mutant genes in fALS
Using whole genome linkage analysis with microsatellite
markers in a set of families with proven ALS cases, a
missense mutation in the D-amino acid oxidase (DAO)
gene located on chromosome 12q22-23 has been
reported in a single three generation pedigree [82]. The
patients with the mutation show classical ALS signs with
a rapid progression and an early bulbar involvement
with a limited decline in cognitive skills [82]. DAO
gene encodes a peroxisomal flavin adenine dinucleotide
(FAD)-dependent oxidase that is seen in neurons and
glial cells of brainstem and spinal cord [83]. R199W
mutations in DAO decrease the cell viability, increase
the formation of ubiquitinated aggregates and enhance
the apoptosis in primary motor neuron cultures [82,83].
When motor neurons are cultured alongside the astro-
cytes expressing R199W mutation, similar features are
documented, indicating that motor neuron death in-
duced by this mutation can be mediated by both cell
autonomous and non-cell autonomous processes [82].
However it is still not clear if the neurodegenerative
effect is from the accumulation of the aberrant proteins
or from an impaired enzyme activity [83,84]. Impaired
enzyme activity leads to the buildup of D-amino acids
like D-serine, an agonist at the glycine site of the
N-methyl-DL-aspartic acid (NMDA) receptor, enhan-
cing glutamate transmission and may exacerbate motor
neuron death [84]. D-serine is increased both in ALS
patients and in SOD1G93A mouse model of ALS [84].
ALS3 has been mapped to chromosome 18q21 in a
large European family [2]. This locus consists of almost
50 genes and the exact gene causing the disease is not
yet to be identified. In one of the pedigrees, a genetic
subtype of ALS, designated ALS7, is linked to chromo-
some 20ptel-p13 [2]. The ALS patients in the family
show the signs of adult onset fALS with rapid disease
progression [2].
Genetics of sALS
The incidence of sALS is more in men than in women
[1,2]. The only clinical feature that distinguishes recog-
nized sporadic from apparently hereditary ALS is older
Table 2 The genetics Of sALS
Gene Protein Chromosomal locus Variant associated with ALS
APEX1 Apurinic Endonuclease DNA repair enzyme 1 14q11.2 SNP associations
ATXN2 Ataxin-2 12q24.12 Poly Q repeats
CHMP2B Chromatin Modifying Protein 2B 3p11.2 Mutations
HFE Haemochromatosis 6p22.2 SNP associations
NEFH Neuro filament Heavy 22q12.2 Deletion and Insertions
SMN1 Survival Motor Neuron 1 5q12.2-q13.3 Abnormal copy number of genes
SMN2 Survival Motor Neuron 2 5q12.2-q13.3 Abnormal copy number of genes
PON 1,2,3 Paraoxonase 7q21.3 SNP associations and mutations
PRPH Peripherin 12q13.12 mutations
VEGF Vascular Endothelial Growth Factor 6p21 Promoter SNP’s
PGRN Progranulin 17q21.31 Deletions
Although the cause of sALS is not known, the crosslink between genetic and environmental factors may contribute to the pathogenesis of sALS. APEX1, ATXN2,
CHMP2B, HFE, NEFH, SMN1, SMN2, PON 1, PON2, PON3, PRPH, VEGF and PGRN are some of the genes associated with sALS. Single Nucleotide Polymorphisms
(SNP’s), Polyglutamine (Poly Q) repeats, abnormal copy number of genes, deletion and insertion mutations are some of the associations found with the genes
known to cause sporadic ALS.
Abbreviations for Table 2: APEX1 Apurinic Endonuclease DNA repair enzyme 1, ATXN2 Ataxin-2, CHMP2B Charged multivesicular body protein 2B, HFE
Haemochromatosis, NEFH Neuro filament Heavy, SMN Survival Motor Neuron, PON Paraoxonase, PRPH Peripherin, VEGF Vascular Endothelial Growth Factor,
PGRN Progranulin.
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reported in hereditary cases including the extrapyram-
idal and cerebellar signs or cognitive involvement have
also been observed in sALS [1-3]. The cause of sALS in
most cases is not known. Several fALS genes such as
C9ORF72, TDP-43, FUS and SOD1 have also been
reported in a small proportion of sALS cases [5]. The
crosslink between genetic and environmental factors
may contribute to the pathogenesis of sALS [1-4];
Table 2. Discovering causative mechanisms in sALS will
facilitate effective treatments and cures for this disease.
Apurinic endonuclease (APEX1)
Mutation analysis conducted on 117 Scottish sALS
patients shows a SNP association ending in a D148E
amino-acid change in APEX1 [85]. However, later on
two other studies fail to confirm this finding [86]. This
might imply that APEX1 mutations may cause sALS in a
particular geographic population. APEX1 participates in
the process of DNA repair and DNA binding of tran-
scription factors and plays a protective role against oxi-
dative stress [87]. APEX1 is a unique redox factor, but
the mutants will lose redox activity and fail to stimulate
cell proliferation. APEX1’s redox function is also shown
to be neuroprotective after exposure to ionizing radi-
ation which produces reactive oxygen species and oxida-
tive DNA damage in neurons [87].
Charged multivesicular body protein 2B (CHMP2B)
A splice site mutation of CHMP2B is first revealed in a
Danish family as a rare cause of FTD accounting for
<1% of the total cases [88]. Patients present with pre-
dominant LMN phenotype and one of the patients evenshows signs of FTD [88,89]. Later on CHMP2B gene
sequencing in 433 ALS patients from England has iden-
tified three missense mutations in fALS and sALS cases
[88]. CHMP2B belongs to CHMP family and this protein
is components of ESCRT-III, a complex involved in deg-
radation of surface receptor proteins and in the traffick-
ing of proteins between plasma membrane, trans-golgi
network and lysosomes [88,89]. CHMP2B mutations in
FTD cases can result in disrupted endosomal structure
which is similar to those seen in alsin mutations [88,89].
In addition, CHMP2B mutations lead to dendritic retrac-
tion and autophagosomal aggregation in cortical neurons
and in hippocampal neurons, implying that CHMP2B is
needed for dendritic spine growth and maturation
[90,91].
Neurofilaments
Neurofilaments are neuronal cytoplasmic intermediate
filaments that form the cytoskeleton of myelinated
axons. Neurofilaments are formed by the subunits of dif-
ferent molecular masses light (NEFL), medium (NEFM),
and heavy (NEFH), which are encoded by different genes
[92]. The abnormal accumulation of neurofilaments in
the cell bodies and proximal axons of motor neurons is
pathognomonic [92]. Association between NEFH and
ALS has been shown in a small group of patients [92].
Overexpression of NEFH, NEFL, and peripherin, as well
as the decreased activity of the dynein protein can cause
paralytic symptoms in mice associated with axonal atro-
phy and motor dysfunction [93]. NEFL is required for
neurofilament assembly; thus, in NEFL null mice, NEFM
and NEFH can not assemble and transport accurately,
leading to reduced levels in axons [93]. Mutations in
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and motor neuropathy, Charcot-Marie-Tooth disease
[94]. The C-terminal of NEFH contains phosphorylation
motifs called lys-ser-pro repeats that have 2 polymorphic
variants of short and long repeats. Homozygosity for the
short repeat allele is associated with sALS in a study
conducted on Russian patients [95]. Deletions and inser-
tions in the C-terminal KSP repeats of NEFH are noted
in some sALS patients [92].
Paraoxonase
The paraoxonases (PON) have 3 units (PON1, PON2,
and PON3) located on 80-kb block of chromosome
7q21.3. PON1 and PON3 are primarily expressed in liver
and reach to the blood where they are associated with
high-density lipoproteins and may protect against ath-
erosclerosis, whereas PON2 is expressed in many tissues
[96]. PON1 and PON2 have been found to express in
mouse brain [96,97]. PON proteins are involved in the
hydrolysis of lactones and in the detoxification of or-
ganophosphate pesticides, neurotoxins and aromatic
esters. The PON gene polymorphisms are found to be as-
sociated with sALS [98,99]. The haploblock of high linkage
disequilibrium spanning PON2 and PON3 is also associ-
ated with sALS [98]. Recently a genomic DNA sequencing
study has identified seven mutations in the PON genes in
patients with fALS and sALS [100]. Furthermore, it has
been shown that neurotoxicity caused by oxidative stress
in PON2 knockout mice is more significant than in wild
type mice, indicating that PON2 might have a neuropro-
tective effect against oxidative stress [96].
Peripherin (PRPH)
PRPH is a type III intermediate filament similar to
neurofilaments. It acts as a cytoskeletal protein and is
present in the neurons of the peripheral nervous system
[101]. PRPH expression is increased in the spinal motor
neurons after neuronal injury, indicating its role in
axonal regeneration [101]. Lewy body-like ubiquitinated
inclusions and Bunina bodies that are seen in some ALS
patients contain PRPH [101]. Overexpression of wild-
type PRPH in transgenic mice develops a selective, large
scale late-onset motor neuron degeneration character-
ized by intermediate filament inclusions [102]. Later on
2 homozygous missense mutations have been identified
in PRPH gene [103]. A study on 122 Italian ALS patients
has identified eighteen sequence variations on PRPH in-
cluding 2 missense variations, namely p.R133P and p.
D141Y [103]. These two variants are predicted to have a
deleterious effect on protein structure or function [103].
PRPH splice variants are noted in certain mouse models
which may contribute to the ALS pathogenesis. A patho-
genic isoform of PRPH (Per61) is found in motor
neurons of mutant SOD1 mice but not in wild-typetransgenic mice [104]. Per61 is not able to assemble
properly, but it can form intracellular aggregates and
then cause neurotoxicity [104]. Per61 is also observed in
the motor neurons from mutant TDP-43 transgenic
mice but not from wild-type TDP-43 mice [105]. Re-
cently, another PRPH splice variant (Per28) is found in
ALS patients, overexpression of which leads to PRPH
aggregation in transgenic mouse model [106].
Survival motor neuron (SMN) 1 AND 2
SMN is in a structure named ‘GEMS’ (Gemini of the
coiled bodies) which has important function in mRNA
metabolism. SMN and its associated protein, SMN-
interacting protein-1 (SIP1), form a complex with several
spliceosomal snRNP (small nuclear Ribo Nucleo Protein)
[107,108]. The impaired assembly and function of the
spliceosome could cause motor neuron degeneration.
Homozygous deletion mutations of SMN1 gene on
chromosome 5 cause the autosomal recessive disorder
spinal muscular atrophy (SMA), a fatal childhood-onset
neuromuscular disease characterized by the degener-
ation of spinal cord motor neurons and subsequent
muscle paralysis [107]. A study on 110 ALS patients and
100 controls found an increased frequency of SMN2
deletions in sALS patients (16%) in controls (4%),
suggesting that SMN2 deletion may be a risk factor for
ALS [108]. In another study on 167 ALS patients for
SMN1 and SMN2 copy number, 16% ALS patients have
an abnormal copy numbers of SMN1 [109]. Although
the involved SMN gene is different in the two studies,
both suggest that the SMN copy numbers is associated
with ALS. Homozygous deletion mutations in SMN
genes are not found in ALS but an abnormal copy num-
bers in SMN1 could increase the risk for ALS [109].
Further studies are needed to clarify the role of the
SMN1 and SMN2 genes in sALS.
Vascular endothelial growth factor (VEGF)
VEGF plays a role in angiogenesis in response to hyp-
oxia. Deletion of hypoxia-responsive element from the
VEGF promoter in mice can cause the late-onset motor
neuron degeneration similar to ALS [110]. Two experi-
ments conducted on mutant SOD1 transgenic mice by
overexpressing VEGF, one through delivery in muscle
and the other through intra-cerebroventricular adminis-
tration, prolong the survival in mutant SOD1 rats [111].
Spinal cords of ALS patients show reduced expression of
VEGF and its receptor [112]. All these lead to the identi-
fication of VEGF as a possible candidate gene for ALS.
Mutation sequencing of the VEGF gene and VEGF pro-
motor in ALS patients fails to identify any specific muta-
tions. However, a study performed on 750 ALS patients
and over 1200 controls from Sweden, Belgium and
England reveal that certain SNPs in the VEGF gene are
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higher risk of ALS, suggesting a link between VEGF
levels and ALS susceptibility [113].
Progranulin (PGRN)
It is a glycoprotein that is a precursor for granulins or
epithelins involved in the development, inflammation
and wound repair [114]. PGRN has also been linked to
tumorigenesis and activated microglia in several neuro-
degenerative diseases [114]. Nonsense and deletion
mutations of PGRN are known to be the cause of ubi-
quitin positive, tau negative FTD (FTDU) [115]. To date,
only a single study links PGRN mutations to ALS [115].
Ataxin-2 (ATXN2)
Ataxin-2, the protein encoded by the ATXN2 gene, con-
tains a polyglutamine (polyQ) tract with normally 22–23
repeats. Intermediate length polyQ repeats (23–34) are
found in ALS patients [97]. ATXN2 and TDP-43 form a
RNA-dependent complex, and longer polyQ repeats
stabilize ATXN2 and increases its interaction with TDP-
43. This leads to enhanced dislocation of TDP-43 into the
cytoplasm in the spinal cord motor neurons in ALS
patients [116]. ATXN2 is also able to interact with
endophilins involved in synaptic vesicle endocytosis [117].
Conclusion
There is a great heterogeneity for genetic spectrum of
fALS and sALS. Several genes in ALS are known to
cause many other neurodegenerative diseases, such as
alsin with PLS and infantile onset ascending hereditary
spastic paralysis (IAHSP), Senataxin with SCAR1 or
AOA2, spatacsin with HSP, VAPB with SMA, FIG 4 with
CMT type 4 J, OPTN with primary open angle glau-
coma. In addition, there is a clinical and pathological
overlap between ALS and FTLD. A number of autoso-
mal-dominant genes have been described as primarily
cause ALS or FTD such as VCP, and TARDBP. The
presence of two neurodegenerative phenotypes within
the same family and even within the same individual
naturally raises question about the genetic and environ-
mental interaction on the disease initiation.
Using linkage analysis, candidate gene studies and gen-
ome wide association studies, about 1/3 fALS and a
small number of sALS have been revealed the disease-
caused genes. However, despite all the progress achieved,
the causes of large majority of sALS remain unknown.
With the advanced genetics technology, we can expect
that the number of genes involved in fALS as well
as sALS will continue to increase. In addition, the
utilization of transgenic animal models may provide
useful tool to study the pathogenesis of ALS. Emphasis
should also be made on elaborating the gene-environ-
ment interactions and crosslink in ALS, as 90% of thecases are sporadic in origin, which may help better
understand the nature of the disease.
It is difficult to predict the future outcome in ALS re-
search, but the identification of novel genes, gene modi-
fiers and the different molecular pathways caused by the
aberrant genes, might advance our research in this area.
Hopefully, the use of the deep sequencing techniques,
transgenic animal models, retrograde studies on avail-
able data and prospective design of future studies, may
help broaden our vision in understanding the ALS gen-
etics and pathogenesis. Strategic approach based on new
ALS genes and drug trials on animal models should
enable us to uncover new treatment modalities.
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